Scancell Holdings PLC represents a strong commitment to innovative cancer immunotherapies. The company's corporate philosophy revolves around developing novel, targeted immunotherapies to treat and prevent cancer. Scancell Holdings PLC focuses on leveraging its expertise in the field of ImmunoBody® and Moditope® platforms to create breakthrough treatments that harness the power of the immune system. With a dedicated team of scientists and researchers, Scancell is driven by a vision to improve patients' lives through effective and personalized cancer treatments. This UK-based biotechnology company is at the forefront of advancing immunotherapeutic solutions and is dedicated to making a positive impact in the fight against cancer.

Scancell Holdings PLC primarily operates in the United Kingdom.

Some significant milestones achieved by Scancell Holdings PLC include the successful development of their innovative ImmunoBody® and Moditope® platforms for cancer immunotherapy. The company has made notable progress in advancing its lead product, SCIB1, through clinical trials, demonstrating promising results in the treatment of melanoma patients. In addition, Scancell has achieved important collaborations and partnerships with renowned organizations, such as Cancer Research UK and the University of Nottingham, further validating their technologies. These achievements highlight Scancell Holdings PLC's dedication to advancing cancer treatment options and building strong industry alliances.

Scancell Holdings PLC is a renowned biotechnology company specializing in the development of novel immunotherapies for the treatment of cancer. Established in 1997, Scancell has pushed the boundaries of cancer research and developed innovative platforms such as ImmunoBody® and Moditope®. The company's cutting-edge technology stimulates the body's immune system to target and eliminate cancer cells selectively. Scancell's dedication to advancing cancer treatment has earned them recognition worldwide. With an experienced team of scientists and a strong commitment to innovation, Scancell Holdings PLC continues to be at the forefront of immunotherapy development, offering hope for improved cancer therapies in the future.

The main competitors of Scancell Holdings PLC in the market include pharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, and Merck & Co. These companies are also involved in developing innovative therapies and treatments for various diseases. As a leading player in the biotechnology sector, Scancell Holdings PLC faces competition in terms of research capabilities, product development, and market presence. However, Scancell Holdings PLC distinguishes itself with its unique immuno-oncology platform and promising pipeline. Its dedication to advancing immunotherapies places the company in a competitive position within the market.

Scancell Holdings PLC is primarily active in the biopharmaceutical industry.

The business model of Scancell Holdings PLC focuses on the development and commercialization of novel immunotherapies to treat cancer. The company utilizes its ImmunoBody® and Moditope® platforms to create innovative and effective treatment options. Scancell aims to leverage its expertise in immunology and cancer biology to develop therapies that activate the patient's immune system to specifically target and destroy cancer cells. By combining these platforms with cutting-edge technologies, Scancell is committed to advancing personalized medicine and improving patient outcomes in the field of oncology.

مُعامل القيمة السوقية إلى الأرباح لـ Scancell Holdings هو ؜-٦٫٧٦.

مُعامِل القيمة إلى المبيعات Scancell Holdings هو 0.

نقاط جودة AlleAktien لـ Scancell Holdings هي 5/10.

لا يمكن حالياً حساب الإيرادات لـScancell Holdings.

صافي الربح المتوقعة Scancell Holdings هو ؜-١٧٫٨٠ مليون. GBP.

Scancell Holdings PLC is a biopharmaceutical company based in the UK that specializes in the development of cancer therapies and vaccines. The company was founded in 1997 and has since become one of the leading companies in this field.

يوزع Scancell Holdings أرباحًا قدرها 0 GBP من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ Scancell Holdings في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـScancell Holdings هو GB00B63D3314.

رمز WKN لـ Scancell Holdings هو A1JZ3D.

الرمز المُختصر لـ Scancell Holdings هو SCLP.L.

خلال آخر 12 شهراً، دفعت Scancell Holdings توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع Scancell Holdings خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 GBP.

نسبة توزيعات الأرباح الحالية لـ Scancell Holdings هي .

Scancell Holdings يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

Scancell Holdings دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 GBP. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

Scancell Holdings يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 GBP من Scancell Holdings المُعلن عنها في ٢١‏/٩‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٢١‏/٩‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ٢١‏/٩‏/٢٠٢٤.

في العام 2023، وزعت Scancell Holdings 0 GBP كأرباح أسهم.

يتم توزيع أرباح Scancell Holdings بالعملة GBP.